Debra Miller

Part of SoftBank Group Corp., Ziff Davis Publishing, Inc. publishes technology-based digital content products. The private company is based in New York, NY. Ziff Davis Publishing was acquired by SoftBank Group Corp. on October 01, 1994 for $198.91 million.

CureDuchenne provides funding for research projects and organizations. The company was founded in 2003 by Paul Miller and Debra Miller and is located in Newport Beach, CA.

Part of Ziff Davis, Inc., PC Magazine operates an online platform that provides lab-based comparative reviews of computing, consumer electronics, business technology, and internet products. The private company is based in New York, NY.

IDG Communications, Inc. operates as a media, data and marketing services company. The firm solutions include media, data, marketing services, events, global partner solutions, and direct marketing. The company is headquartered in Framingham, MA.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

CureDuchenne Ventures LLC (CureDuchenne Ventures) is a venture capital subsidiary of CureDuchenne, founded in 2014 by Debra Miller. The firm is headquartered in Newport Beach, California.

Exonics Therapeutics, Inc. develops therapies for neuromuscular diseases. It also develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of duchenne muscular dystrophy mutations. The company was founded by Eric N. Olson in February 2017 and is headquartered in Cambridge, MA.